Evofem Biosciences (EVFM) Announces Padagis Will Not Seek FDA Approval to Market a Generic Version of Phexxi Until Evofem's Phexxi Patents Expire streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Padagis Determined They Will Not Challenge the Phexxi Patents
Evofem Has Phexxi Patent Protection Through 2033
SAN DIEGO, Sept. 27, 2023 /PRNewswire/ Evofem Biosciences, Inc., .
/PRNewswire/ Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced financial results for the first quarter of 2023, including growth in net product sales.
Increased net product revenue 37% in the first quarter of 2023 vs. prior year quarter Reduced operating expenses 72% Decreased loss from operations by 88% Reaffirms path to. | June 17, 2023
VYNE Therapeutics Reports Second Quarter 2021 Financial globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.